Rhinitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for rhinitis. 3 active patents protecting 1 drugs from 1+ originators. First major cliff: 2035. Daily refresh.

1
Approved drugs
3
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Rhinitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (multiple manufacturers) 3 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating rhinitis. Each bar = one year. Y-axis scaled to peak year (3 patents).

3
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Mucinex
guaifenesin
 Generic (multiple manufacturers) 3 62 — 2035-11-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10105324 Mucinex method of use 62 2035-11-13
9549907 Mucinex method of use 62 2035-11-13
9808431 Mucinex method of use 62 2035-11-13

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10105324 Mucinex method of use 62 2035-11-13
9549907 Mucinex method of use 62 2035-11-13
9808431 Mucinex method of use 62 2035-11-13

Related